835 reports of this reaction
2.8% of all UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE reports
#6 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #6 most commonly reported adverse reaction for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 835 FDA adverse event reports linking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.8% of all 30,147 adverse event reports for this drug.
Patients taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 835 FDA reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.8% of all adverse event reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience product dose omission issue while taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.